{"id":203279,"date":"2026-08-14T10:56:04","date_gmt":"2026-08-14T05:26:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=203279"},"modified":"2026-08-14T10:56:05","modified_gmt":"2026-08-14T05:26:05","slug":"thyrocare-technologies-share-price-promoter-sells-stake-august-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/thyrocare-technologies-share-price-promoter-sells-stake-august-2026\/","title":{"rendered":"Thyrocare Technologies Share Price in Focus as Promoter Docon Technologies Sells 8.9 Percent Stake for Rs 821.7 Crore to 14 Institutional Investors on 14 August 2026"},"content":{"rendered":"
<\/div>\n

Thyrocare Technologies share price: Docon (API Holdings sub.) sells 1.31Cr shares (8.9%) at Rs 624 = Rs 821.7Cr to 14 institutions. Additional 10L at Rs 631.71. Docon held 60.92% as of Jun 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Docon Technologies, the promoter entity and API Holdings subsidiary, has sold 1.31 crore equity shares (8.9 percent of paid-up equity) of Thyrocare Technologies at Rs 624 per share for Rs 821.7 crore on 14 August 2026. The block was absorbed by 14 domestic and global institutional investors including HSBC MF, Kotak Life Insurance, ABSL AMC, ICICI Prudential, Morgan Stanley Asia Singapore, and Kuwait Investment Authority. Separately, Docon sold 10 lakh shares at Rs 631.71 per share on the NSE for Rs 63.17 crore. As of June 2026, Docon held a 60.92 percent stake in Thyrocare.<\/p>\n<\/div>\n

The Thyrocare Technologies share price block deal today is one of the largest single-session promoter stake sales in the diagnostics sector this year. At Rs 821.7 crore for the primary block alone, this is a significant transaction that reshuffles Thyrocare’s institutional ownership. The 14 institutional buyers \u2014 a diverse mix spanning Indian mutual funds, insurance companies, foreign portfolio investors, and global sovereign wealth \u2014 absorbing the entire block at Rs 624 per share without any visible discount signals that the Thyrocare Technologies share price institutional demand at current levels is robust. When a block of this size moves cleanly without market disruption, it’s a reasonably healthy sign for the stock’s liquidity and institutional support.<\/p>\n

Docon Technologies, as a subsidiary of API Holdings, has been progressively reducing its Thyrocare stake since the 2021 acquisition. Promoter stake dilutions of this scale are common in PE\/VC-backed companies as the original acquirer seeks to return capital to its own investors over time. The combined Rs 884.87 crore raised today \u2014 Rs 821.7 crore from the institutional block plus Rs 63.17 crore from the NSE transaction \u2014 represents meaningful liquidity for API Holdings, which continues to operate in the broader digital healthcare space.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n